MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab versus Avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).
- Citation:
- J Clin Oncol vol 40 (16_suppl) TPS4607
- Meeting Instance:
- ASCO 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U24 CA196171, U10CA180863 (CCTG)
- Corr. Author:
- Authors:
- Shilpa Gupta Matthew D. Galsky Michael J. Morris Karla V. Balman Ronald Chen Timothy M. Chan Laurent Dercle Tareq Al-Baghdadi Srikala Sridhar Aihua Edward Yen Petros Grivas Shiva Baghaie Alan Tan Jonathan E. Rosenberg
- Networks:
- KANSAS, LAPS-NY016, LAPS-TN008, MCRC, NY021, OH027
- Study
- Alliance-A032001
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: